Comment on: A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma

Detalles Bibliográficos
Autores principales: Baidoun, Firas, Merjaneh, Zahi, Abd-Elhay, Fatma Abd-Elshahed, Kamel, Mohamed Gomaa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214216/
https://www.ncbi.nlm.nih.gov/pubmed/34147028
http://dx.doi.org/10.1016/j.tranon.2021.101156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214216/
https://www.ncbi.nlm.nih.gov/pubmed/34147028
http://dx.doi.org/10.1016/j.tranon.2021.101156

Ejemplares similares